| 发明名称 | Antitumor agent including low-dose irinotecan hydrochloride hydrate | ||
| 摘要 | Provided is a novel combination therapy using an FTD/TPI combination drug which exhibits remarkable antitumor effects, and few side effects.;An antitumor agent is characterized in that the FTD/TPI combination drug is administered, using a reduced amount of trifluridine, at a dose in the range of 35 to 70 mg/m2/day and CPT-11 is administered at a dose in the range of 45 to 144 mg/m2/day. | ||
| 申请公布号 | US9616081(B2) | 申请公布日期 | 2017.04.11 |
| 申请号 | US201414779759 | 申请日期 | 2014.03.27 |
| 申请人 | TAIHO PHARMACEUTICAL CO., LTD. | 发明人 | Okabe Hiroyuki |
| 分类号 | A61K31/70;A01N43/04;A61K31/7072;A61K31/4745;A61K31/506;A61K31/513;A61K31/706;A61K31/7064;A61K31/7068 | 主分类号 | A61K31/70 |
| 代理机构 | Oblon, McClelland, Maier & Neustadt, L.L.P. | 代理人 | Oblon, McClelland, Maier & Neustadt, L.L.P. |
| 主权项 | 1. A method for treating a solid cancer, comprising: administering to a subject a combination drug comprising trifluridine and tipiracil hydrochloride in a molar ratio of 1:0.5 at a dose of 35 to 70 mg/m2/day of trifluridine, and 45 to 144 mg/m2/day of irinotecan hydrochloride hydrate. | ||
| 地址 | Chiyoda-ku JP | ||